Neurology Alert – January 1, 2005
January 1, 2005
View Issues
-
Natalizumab Receives Accelerated FDA Approval For MS
Natilizumab will become an important option for newly diagnosed MS patients starting treatment, or for patients currently on interferon beta-1a or glatiramer acetate with refractory breakthrough disease. -
Cloning of PARK8: LRRK2 in Autosomal, Dominant Late-Onset Parkinson’s Disease
LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders associated with Parkinsonism. -
A New Approach Preventing Amyloid Aggregation May Result in Novel Therapeutics For Alzheimer’s Disease
This strategy yields potent inhibitors of A-beta aggregation and could lead to therapeutics for Alzheimers disease and other forms of neurodegeneration. -
Intermediate Filament Diseases
Further research will be required to understand the pathogenesis of these disorders. -
TBI: CRASH Kills Corticosteroids
There is an increase in mortality with methylprednisolone in the 2 weeks after head injury. The cause of the rise in risk of death within 2 weeks is unclear. -
Sensory Polyradiculopathy
This condition preferentially affects large myelinated fibers of the posterior roots, may respond favorably to treatment, and may be a restricted form of chronic inflammatory demyelinating polyradiculoneuropathy. -
A New Genetic Defect in Charcot-Marie-Tooth Disease Links It to Mitochondrial Dysfunction
The present findings raise the possibility that new effective therapies may be developed for CMT2A, which target the underlying pathophysiology. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch - Hypertension: Therapy vs Calcium Channel Antagonists
Researchers from Sweden performed a meta-analysis of 9 randomized, controlled trials that looked at the effectiveness of atenolol on cardiovascular morbidity and mortality in patients with hypertension.